Primary Outcome Measures:
- Meningococcal rSBA titres in group A and group B [ Time Frame: One month after vaccination with meningococcal vaccine 134612 and the first dose of Twinrix. ] [ Designated as safety issue: No ]
- Hepatitis A seroconversion and Hepatitis B seroprotection in group A and group C [ Time Frame: One month after the third dose of Twinrix. ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Vaccine response to meningococcal antigens in group A and group B [ Time Frame: One month after vaccination with meningococcal vaccine 134612 and the first dose of Twinrix. ] [ Designated as safety issue: No ]
- Anti-meningococcal polysaccharide concentrations in group A and group B [ Time Frame: Prior to and one month after vaccination with meningococcal vaccine 134612 and the first dose of Twinrix. ] [ Designated as safety issue: No ]
- Anti-tetanus toxoid antibody concentration in group A and group B. [ Time Frame: Prior to and one month after vaccination with meningococcal vaccine 134612 and the first dose of Twinrix. ] [ Designated as safety issue: No ]
- Meningococcal rSBA titres [ Time Frame: One month after the third dose of Twinrix in Group A and seven months after vaccination in Group B. ] [ Designated as safety issue: No ]
- Anti-meningococcal polysaccharide concentrations [ Time Frame: One month after the third dose of Twinrix in Group A and seven months after vaccination in Group B. ] [ Designated as safety issue: No ]
- IgG hepatitis A virus antibody concentration in Group A and Group C. [ Time Frame: Prior to first dose of Twinrix and one month after the third dose of Twinrix ] [ Designated as safety issue: No ]
- IgG hepatitis B surface antigen antibody concentration in Group A and Group C. [ Time Frame: Prior to first dose of Twinrix and one month after the third dose of Twinrix ] [ Designated as safety issue: No ]
- Occurrence of solicited local and general symptoms. [ Time Frame: During the 4-day follow-up period after each vaccine dose. ] [ Designated as safety issue: Yes ]
- Meningococcal rSBA titres in group A and group B [ Time Frame: Prior to vaccination with meningococcal vaccine 134612 and the first dose of Twinrix. ] [ Designated as safety issue: No ]
- Occurrence of unsolicited symptoms. [ Time Frame: Up to one month after each vaccine dose. ] [ Designated as safety issue: Yes ]
- Occurrence of specific adverse events of rash, new onset of chronic illness(es), conditions prompting emergency room visits and physician office visits not related to common illnesses and any events related to lack of meningococcal vaccine efficacy. [ Time Frame: Throughout the entire study. ] [ Designated as safety issue: Yes ]
- Occurrence of serious adverse events [ Time Frame: Throughout the entire study. ] [ Designated as safety issue: Yes ]
All subjects of groups A and B will have 4 blood samples taken, all subjects of group C will have 3 blood samples taken.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.